Controlling the digital ulcerative disease in systemic sclerosis is associated with improved hand function.

[1]  L. Mouthon,et al.  Changes over Time and Responsiveness of the Cochin Hand Function Scale and Mouth Handicap in Systemic Sclerosis Scale in Patients with Systemic Sclerosis: A Prospective Observational Study , 2016, American journal of physical medicine & rehabilitation.

[2]  L. Mouthon,et al.  Pathophysiology of systemic sclerosis: state of the art in 2014. , 2014, Presse medicale.

[3]  M. Richard,et al.  Ischemic Digital Ulcers Affect Hand Disability and Pain in Systemic Sclerosis , 2014, Journal of Rheumatology.

[4]  Oliver Distler,et al.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. , 2013, Arthritis and rheumatism.

[5]  A. Murray,et al.  A prospective study of systemic sclerosis-related digital ulcers: prevalence, location, and functional impact , 2013, Scandinavian journal of rheumatology.

[6]  S. Bombardieri,et al.  Oral sildenafil in skin ulcers secondary to systemic sclerosis , 2011, Scandinavian journal of rheumatology.

[7]  M. Matucci-Cerinic,et al.  Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis. , 2011, Autoimmunity reviews.

[8]  L. Mouthon,et al.  Impact of systemic sclerosis on occupational and professional activity with attention to patients with digital ulcers , 2011, Arthritis care & research.

[9]  M. Baron,et al.  Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the Canadian Scleroderma Research Group registry , 2011, Arthritis care & research.

[10]  J. Pope,et al.  Differences in disability as measured by the Health Assessment Questionnaire between patients with and without digital ulcers in systemic sclerosis: a post hoc analysis of pooled data from two randomised controlled trials in digital ulcers using bosentan , 2010, Annals of the rheumatic diseases.

[11]  M. Mayes,et al.  Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial , 2010, Annals of the rheumatic diseases.

[12]  M. Baron,et al.  The Minimally Important Difference in Clinical Practice for Patient-centered Outcomes Including Health Assessment Questionnaire, Fatigue, Pain, Sleep, Global Visual Analog Scale, and SF-36 in Scleroderma , 2010, The Journal of Rheumatology.

[13]  G. Burmester,et al.  Concise Report , 2022 .

[14]  E. Hachulla,et al.  Clinical Features of Scleroderma Patients With or Without Prior or Current Ischemic Digital Ulcers: Post-Hoc Analysis of a Nationwide Multicenter Cohort (ItinérAIR-Sclérodermie) , 2009, The Journal of Rheumatology.

[15]  J. Gerss,et al.  Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors , 2009, The British journal of dermatology.

[16]  Marina Anderson,et al.  Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis. , 2009, Arthritis and rheumatism.

[17]  M. Revel,et al.  Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis , 2009, Annals of the rheumatic diseases.

[18]  E. Hachulla,et al.  Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. , 2007, The Journal of rheumatology.

[19]  M. Revel,et al.  Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. , 2007, Arthritis and rheumatism.

[20]  U. Müller-Ladner,et al.  Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database , 2007, Annals of the rheumatic diseases.

[21]  C. Denton,et al.  Digital ulcers: overt vascular disease in systemic sclerosis. , 2006, Rheumatology.

[22]  D. Abraham,et al.  Overview of pathogenesis of systemic sclerosis. , 2006, Rheumatology.

[23]  T. Krieg,et al.  Skin disease: a cardinal feature of systemic sclerosis. , 2006, Rheumatology.

[24]  Richard W. Martin,et al.  Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study , 2006, Annals of the rheumatic diseases.

[25]  Y. Allanore,et al.  Radiological hand involvement in systemic sclerosis , 2006, Annals of the rheumatic diseases.

[26]  O. Chassany,et al.  Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ) , 2005, Clinical Rheumatology.

[27]  M. Mayes,et al.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. , 2004, Arthritis and rheumatism.

[28]  J. Poole,et al.  Reliability and validity of the Duruoz Hand Index in persons with systemic sclerosis (scleroderma). , 2004, Arthritis and rheumatism.

[29]  Richard W. Martin,et al.  Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. , 2002, Arthritis and rheumatism.

[30]  T. Medsger,et al.  Criteria for the classification of early systemic sclerosis. , 2001, The Journal of rheumatology.

[31]  T. Perneger,et al.  The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. , 1998, Journal of clinical epidemiology.

[32]  M Sullivan,et al.  The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. , 1998, Journal of clinical epidemiology.

[33]  J Fermanian,et al.  Development and validation of a rheumatoid hand functional disability scale that assesses functional handicap. , 1996, The Journal of rheumatology.

[34]  L. Kaufman,et al.  Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study , 1994, Annals of Internal Medicine.

[35]  A. Silman,et al.  Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. , 1993, The Journal of rheumatology.

[36]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[37]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[38]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[39]  E. Huskisson.  Measurement of pain. , 1974, Lancet.

[40]  R. Wise,et al.  Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. , 1992, The Journal of rheumatology.